Manuel Vazquez-Ramos

A Coruna, GA 15009, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors-Health-EpiGEICAM Study.

Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors-Health-EpiGEICAM Study.

Journal: Cancers

Published: September 09, 2022

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

Journal: The New England journal of medicine

Published: December 16, 2021

Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype.

Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype.

Journal: Nutrients

Published: August 26, 2020

First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study.

First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study.

Journal: Journal of geriatric oncology

Published: February 11, 2020

Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study.

Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study.

Journal: Scientific reports

Published: September 16, 2019

Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study.

Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study.

Journal: OncoTargets and therapy

Published: October 02, 2018

Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study.

Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study.

Journal: Scientific reports

Published: July 05, 2018

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 03, 2016

Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.

Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 04, 2014

MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients.

MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients.

Journal: Neoplasia (New York, N.Y.)

Published: April 24, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026